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Abstract
Background
Increasing volumes of data and computational capacity afford unprecedented opportunities
to scale up infectious disease (ID) mapping for public health uses. Whilst a large number of
IDs show global spatial variation, comprehensive knowledge of these geographic patterns
is poor. Here we use an objective method to prioritise mapping efforts to begin to address
the large deficit in global disease maps currently available.
Methodology/Principal Findings
Automation of ID mapping requires bespoke methodological adjustments tailored to the epi-
demiological characteristics of different types of diseases. Diseases were therefore
grouped into 33 clusters based upon taxonomic divisions and shared epidemiological char-
acteristics. Disability-adjusted life years, derived from the Global Burden of Disease 2013
study, were used as a globally consistent metric of disease burden. A review of global
health stakeholders, existing literature and national health priorities was undertaken to as-
sess relative interest in the diseases. The clusters were ranked by combining both metrics,
which identified 44 diseases of main concern within 15 principle clusters. Whilst malaria,
HIV and tuberculosis were the highest priority due to their considerable burden, the high pri-
ority clusters were dominated by neglected tropical diseases and vector-borne parasites.
Conclusions/Significance
A quantitative, easily-updated and flexible framework for prioritising diseases is presented
here. The study identifies a possible future strategy for those diseases where significant
knowledge gaps remain, as well as recognising those where global mapping programs
have already made significant progress. For many conditions, potential shared epidemio-
logical information has yet to be exploited.
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Author Summary
Maps have long been used to not only visualise, but also to inform infectious disease con-
trol efforts, identify and predict areas of greatest risk of specific diseases, and better under-
stand the epidemiology of disease over various spatial scales. In spite of the utilities of such
outputs, globally comprehensive maps have been produced for only a handful of infectious
diseases. Due to limited resources, it is necessary to define a framework to prioritise which
diseases to consider mapping globally. This paper outlines a framework which compares
each disease’s global burden with its associated interest from the policy community in a
data-driven manner which can be used to determine the relative priority of each condition.
Malaria, HIV and TB are, unsurprisingly, ranked highest due to their considerable health
burden, while the other priority diseases are dominated by neglected tropical diseases and
vector-borne diseases. For some conditions, global mapping efforts are already in place,
however, for many neglected conditions there still remains a need for high resolution
spatial surveys.
Introduction
Maps provide an essential evidence-base to support progress towards global health commit-
ments [1]. For example, they provide important baseline estimates of disease limits [2–7],
transmission [8–10] and clinical burden [11–14]; underpin surveillance systems and outbreak
tracking [15,16]; help target resource allocation from the macro- [17,18] through the meso-
[19–22] to the micro-scale [23]; and inform international travel guidelines [24–26]. Significant
developments in mapping techniques have occurred over the last few decades, particularly
through the use of species distribution models and model-based geostatistics [1,27]. Similarly,
disease data has become more widespread and easier to share [28]. Despite these advances
however, a recent review of 355 clinically-significant infectious diseases (IDs) indicated that of
the 174 IDs for which an opportunity for mapping was identified, only 4% had been compre-
hensively mapped [1]. For many of these conditions, there is a significant shortfall between ex-
isting maps and what can be achieved with contemporary methods and datasets.
Traditional mapmaking has focussed on a vertical, single-species approach, requiring highly
labour intensive, and therefore expensive, manual data identification and assembly [13,21,29–
31]. The present era of open-access big data, high computational capacity, and rapid software
development offers new opportunities for scaling-up the spatial mapping of IDs, primarily
through the automation of data gathering and geopositioning but ultimately also to mapping.
The Atlas of Baseline Risk Assessment for Infectious Disease (abbreviated ABRAID, as in, “to
awake”) is a developing software platform designed to exploit this opportunity and has the am-
bition to produce continuously updated maps for 174 IDs globally [28]. Realising automation
of data retrieval and positioning at this scale is a practically non-trivial but conceptually simple,
logistic scaling exercise. In order to automate mapping for each ID so that it is continuously
updated and improved as new information becomes available, the spatial inference methods
used need to be tailored to each unique ID epidemiology [28]. In some cases this will require
disease-specific methodological developments. This requires substantial investment, so an ob-
jective and systematic approach is required to determine the order in which IDs are to
be mapped.
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The first stage in this process is to organise all IDs using a schema based upon shared bio-
logical and epidemiological traits; for example, “the mosquito-borne arboviruses”. Such groups
will likely have similar mapping requirements, enabling synergies in data collation, covariate
selection, increased efficiency (i.e. in software development), and more robust validation of
outputs [32,33]. We refer to these disease groups as “mapping clusters” and they form the basic
architecture of the prioritisation process.
To rationally prioritise mapping of these conditions, the diseases within each mapping clus-
ter were evaluated based upon their global burden (both morbidity and mortality), as well as
the disease’s importance amongst public health stakeholders. Data inputs are quantitative in
nature and reliant on either independently derived data or data sourced from entire communi-
ties rather than selected expert individuals. Therefore, this proposed framework is unaffected
by much of the subjectivity associated with other prioritisation studies, and also provides a
platform for rapidly incorporating changes to existing diseases, as well as emerging novel pub-
lic health threats. The prioritisation exercise helps to guide the order in which diseases are
mapped to best support public health priorities; we argue that all relevant diseases can and
should eventually be mapped.
A comprehensive atlas of IDs is of central importance in providing geographical context to
the understanding of tropical disease and global health [34–36]. Moreover, as the atlas becomes
more complete the overlay of maps will provide opportunities for investigating patterns of
global disease diversity [37,38] and the process of disease emergence [39].
Methods
Method summary
In order to generate disease prioritisation standards, diseases with shared taxonomy and trans-
mission characteristics were grouped together to create clusters. Diseases within each cluster
were evaluated based upon two factors reflecting their importance from a public health per-
spective: (a) the global burden of the disease and (b) the current public health focus on the con-
dition. Both metrics were assessed simultaneously in order to rank the clusters, and specific
diseases were then identified for prioritisation.
Selection of diseases for mapping
This study aimed to be comprehensive in its scope of IDs. All diseases identified in a previous
review as meriting mapping were included [1]. This earlier study categorised 355 diseases into
five classes: Option 1, indicating that the disease was unsuitable for occurrence based mapping
methods; Option 2, mapping the observed occurrence of the disease; Option 3, mapping the
maximum potential range of the disease using knowledge of vector, intermediate host and res-
ervoir species; Option 4, using niche mapping methods such as boosted regression trees; and
Option 5, where sufficient data exist to allow for global maps of variation in prevalence of in-
fection and/or disease. Option 1 diseases included those that showed no sustained spatial varia-
tion in occurrence (i.e. had a cosmopolitan distribution) and had insufficient evidence to allow
for the global mapping of variation in prevalence using advanced statistical methods such as
model-based geostatistics. In cases where such information does exist, these diseases were pro-
moted to Option 5 status. Revisions to theHay et al. (2013) paper have led to the inclusion of
tuberculosis, ascariasis, trichuriasis and trachoma—all previously listed as Option 1—as Op-
tion 5 diseases. Further revisions included the exclusion of New and Old World Spotted Fever
Rickettsiosis and New and Old World Phlebovirus because their constituent diseases were in-
cluded. In addition, Plasmodium knowlesi was included due to the increasing appreciation of
its significance to human health in Southeast Asia [40,41]. The new revised total of diseases
Prioritising Infectious Disease Mapping
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0003756 June 10, 2015 3 / 21
that warrant mapping was therefore 176. Those diseases not considered for mapping due to
Option 1 classification are outlined and justified in the Supporting Information.
Creating disease clusters
Diseases were grouped into clusters based on characteristics relevant to spatial epidemiology.
Diseases were placed in the same cluster if they had the potential to mutually reinforce each
other in terms of data assembly, mapping requirements and cross-validation of data by com-
parison of outputs. Clustering classifications were therefore based on the key factors influenc-
ing the approach taken for mapping.
At the coarsest level, pathogens were grouped by agent type (virus/bacteria/fungus/other)
and the larger agent groupings were split into specific phyla (e.g. Nematoda and Platyhel-
minths) [42]. These relatively coarse groups reflect fundamental differences in life histories
and epidemiology as well as the most basic taxonomic divisions. Within these broad groupings,
the mode of transmission was used to create the final disease clusters. This is an important fac-
tor when mapping IDs, as the mode of transmission has a large influence on which abiotic cor-
relates are relevant to the mapping process. For instance, the transmission limits of vector-
borne diseases are restricted in part by the environmental suitability for the vector species in
question, thus diseases spread by similar vectors will share covariates [43]. Similarly, sexually-
transmitted diseases are likely to share mapping methods linked to human distribution and be-
haviour, whilst pathogens spread by water contact would share common traits linked to the en-
vironment; these groupings can therefore be logically considered together within a mapping
framework. The mode of transmission classifications are defined in the previous publication
[1].
Assessing disease burden
The burden of each disease was assessed using the disability-adjusted life year (DALY) esti-
mates from the 2013 Global Burden of Disease Study (GBD 2013) [44,45]. DALYs quantify
both morbidity and mortality attributed to each disease and therefore better capture the total
impact of a disease than do clinical cases or mortality alone [44,45]. The GBD’s systematic ap-
proach across a wide spectrum of diseases provides an extremely valuable resource from which
to compare the relative impact of diseases on human health.
Wherever possible, direct links were made between the GBD estimates and diseases in the
mapping list. The GBD disease categories, which are based upon the International Classifica-
tion of Diseases and Related Health Problems (ICD-10) [46], do not always specify particular
infectious agents, but rather focus on the clinical symptoms of infection, or non-specified dis-
ease groups. These aggregated DALY estimates had to be split across the relevant causative dis-
eases in the mapping list, therefore theHay et al. (2013) study was reconciled with the ICD-10
codes and then GBD categories in order to disaggregate the broader classifications such as
“other diarrheal diseases” and “other neglected tropical diseases”. The full process is outlined
in the associated Supporting Information, S1 Text.
Overall, 11 of the 176 mapping diseases could not be reconciled to the GBD categories.
Some were not considered due to having unknown pathogenic agents (e.g. tropical sprue) and
others were very rare and fell into ICD-10 categories that were assigned over various groupings
(e.g. pentastomiasis). These diseases were allocated a nominal DALY of 100; this value, while
arbitrary, is low enough to avoid skewing the analysis. For each cluster, the total DALYs for all
diseases was calculated and contributed to the final analysis.
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Assessing global health community interest
Of equal importance is the need to produce maps for those diseases where there is the greatest
demand, whether from international organisations or from local public health authorities.
Measuring this factor was achieved by surveying a representative subset of potential end-users,
to identify which diseases have been prioritised by major public health stakeholders: state-
funded public health agencies, private companies (e.g. vaccine developers), political bodies,
non-governmental advocates and practitioners, as well as the scientific research community.
For each disease, the final policy score was the sum of three component scores: public health,
stakeholder interest, status as a notifiable disease, and h-index.
Cases from the different categories of public health stakeholders were included to capture
the spectrum of interest groups (see S1 Text for full listing). Each organisation’s mission state-
ment and project pages were reviewed to identify the diseases contained in their public health
portfolio. Depending on the type of stakeholder, this would indicate that the organisation
would, for example, dedicate funding and effort towards control of that disease, advocate for
the disease to governments or public health agencies, or dedicate research funding to the dis-
ease. Each disease was allocated one point per stakeholder reporting an interest in it. An inclu-
sive approach was followed, whereby diseases were considered to be of interest to a
stakeholder, irrespective of any hierarchy within the agency’s prioritisation system.
Another point was allocated to diseases which were notifiable to national disease control
agencies. In order to mitigate spatial bias in the notifiable disease listed by different agencies, a
search for countries which had readily-accessible and clearly defined domestic policy relating
to named pathogens was performed, and one country from each of the main GBD defined re-
gions was selected: USA (High Income), Brazil (Latin America and the Caribbean), Zambia
(sub-Saharan Africa), United Arab Emirates (North Africa and the Middle East), India (South
Asia), Malaysia (South East Asia, East Asia and Oceania) and Croatia (Central and Eastern Eu-
rope and Central Asia). Interest in these diseases at a domestic level suggests that there will be
interest in maps of these diseases, as demonstrated by the presence of subscription-only online
databases of maps including GIDEON [47] and the rapid expansion of real-time maps to
which physicians are encouraged to contribute [15,28].
Academic output, a proxy of funder agency awards, but also of high-quality data availability
[1], was quantified based on the h-index of each disease [48], as reported by Scopus [49]. More
commonly used to assess a scientist’s productivity and impact, the h-index is used here to
quantify the level of active interest across the academic community in each disease [50]. The h-
index is the number of published papers (referring to a particular disease) that have been cited
by at least as many other papers. In other words, an h-index of 7 signifies that 7 published pa-
pers including that disease name have been cited at least 7 times. For each disease in turn, Sco-
pus citation numbers were generated for all publications referring to the disease (document
search for "Disease Name" in "Article Title, Abstract, Keywords"). This Scopus search generates
a Citation Tracker file showing the number of citations to each publication referring to the
"Disease Name". Diseases were then categorised according to their h-index. Those for which
there was evidence of very high scientific output scored 2 (h-index>100), those with interme-
diate h-index (>50–100) scored 1.5, while diseases with h-index of<50 scored 1.
The diseases classified as Option 4 (use niche modelling methods) and Option 5 (model
prevalence or incidence) have the most epidemiological data available and have the greatest po-
tential to benefit from a dedicated mapping exercise, but also require the most resources. Op-
tion 2 and 3 diseases are data-poor and both require mapping of occurrence data only [1], and
therefore are significantly less time-intensive to map, limited to more simplistic analyses, than
those diseases categorised as Option 4 and 5. Option 3 disease mapping relates potential
Prioritising Infectious Disease Mapping
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transmission limits to aspects of vector biology. In cases where Option 4 and 5 diseases also
have the same vector, the Option 3 disease will be considered as part of mapping these comple-
mentary diseases; where this is not the case, a disease’s transmission limits can be assessed
through a mixture of literature surveys and occurrence data overlap. Option 4 and 5 diseases
within the disease clusters were therefore prioritised and for each cluster, the average policy
score for the Option 4 and 5 diseases was calculated and contributed to the final analysis. These
diseases should be the primary focus of future cartographic efforts as these require the most at-
tention and bespoke inputs to be generated.
Mapping prioritisation ranking of diseases
The final step in the process was to combine these assessments to produce a ranking of disease
clusters and therefore recommend diseases to prioritise for mapping. Each cluster was plotted
on a graph based on its total DALYs and the average policy priority of its Option 4 and 5 dis-
eases. Option 2 and 3 diseases were included in the cluster DALY scores in order to reflect the
relative importance that each cluster represented in terms of burden of disease. One cluster
may consist of a large number of minor diseases which, as a collective grouping, represent a sig-
nificant problem—by retaining the DALY score, this burden is reflected, With the policy prior-
ity score however, the opposite is the case; inclusion of multiple low scoring diseases would
down-weight the cluster as a whole. In scenarios where clusters consist of a diverse grouping of
pathogens, averaging policy score across all conditions misrepresents those with a high policy
priority and therefore masks these diseases in comparison to clusters that only consist of those
diseases with high policy priority scores.
Each cluster was then evaluated based upon its distance from a hypothetical cluster which
had the highest DALYs (i.e. that of HIV) and the highest policy score (i.e. that of Malaria) rela-
tive to a line drawn from this cluster to the origin; those closer to this hypothetical cluster,
along this axis, were prioritised higher. As a result, the relative influence of burden and policy
priority could be considered both simultaneously and independently. Within each cluster, the
diseases to be prioritised (i.e. Option 4 or 5) were then reported (Table 1). The code to replicate
this methodology is freely available from: https://github.com/SEEG-Oxford/prioritisation.
Results
Organization of the mapping clusters
The 176 diseases identified as having a rationale for mapping were organised into 33 clusters,
based upon the biological and taxonomic classifications of the causative pathogen, modes of
transmission and the mapping method recommended in a previous review [1] (Fig 1). Seven of
these clusters included only a single disease due to their unique transmission within their
broader taxonomic grouping (HIV, poliomyelitis, avian influenza, pythiosis, South American
bartonellosis, tuberculosis and babesiosis). Conversely, the mosquito-borne arbovirus cluster
was the largest cluster, consisting of 26 diseases, many of which have the potential to benefit
from modelled maps.
Prioritising mapping diseases
Fig 2 brings together the two indices selected to prioritise diseases for mapping—disability ad-
justed life-year (DALY) burden and relative stakeholder interest. These plots demonstrate that
the HIV, malaria and tuberculosis clusters are exceptional in representing an overwhelming
share of DALY burden [51] and being of highest priority to the global health community with
their placement in the top right quadrant of the graph. These three clusters contain five
Prioritising Infectious Disease Mapping
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Table 1. Clusters indicated asmapping priorities with their constituent diseases recommended for distribution modelling and current global map-
ping projects identified.
Cluster (main diseases to map / total
diseases in cluster)
Diseases within cluster, to
map
Total cluster
DALYs
Average policy
score
Current global mapping
projects
1. Malaria (n = 3/5) Plasmodium falciparum 65,493,135 11.8 MAP [13,29,40]; WHO [81]
P. knowlesi
P. vivax
2. HIV (n = 1/1) HIV 69,480,661 11 GBD [51]; UNAIDS [82]
3. Tuberculosis (n = 1/1) Tuberculosis 49,816,215 11 GBD [51]
4. Food/Water-borne (Bacteria) (n = 1/4) Cholera 9,962,003 8
5. Water-borne (Platyhelminth) (n = 3/7) Schistosoma haematobium 3,062,843 7.7 GAHI [83]; Global NTD
database [31]
S. japonicum
S. mansoni
6. Trypanosomiasis (n = 2/2) African trypanosomiasis 728,564 7.5 WHO [68,84]
American trypanosomiasis
7. Filariasis (n = 3/3) Bancroftian ﬁlariasis 2,022,099 6.2 GAHI [85]
Brugia malayi
B. timori
8. Soil Transmitted Helminths (n = 3/3) Ascariasis 4,029,403 5.3 GAHI [5,14]
Hookworm
Trichuriasis
9. Leishmaniasis (n = 3/3) Cutaneous leishmaniasis (Old
World)
4,283,139 5.2 SEEG [8]
Cutaneous leishmaniasis
(New World)
Visceral leishmaniasis
10. Unknown agent (n = 1/4) Tropical sprue 3,609,400 4
11. Picornaviridae (n = 1/1) Polio 116,065 6 The Global Polio Eradication
Initiative [86]
12. Food/Water-borne (Nematode) (n = 1/13) Dracunculiasis 422,476 2.5
13. Fly-borne (Nematode) (n = 2/5) Loiasis 711,246 4.3 WHO and APOC [87] [88]
Onchocerciasis
14. Direct contact (Bacteria) (n = 4/6) Anthrax 1,030,777 4
Brazilian purpuric fever
Leprosy
Trachoma GAT [10,89]
15. Mosquito-borne (Virus) (n = 15/26) Barmah Forest disease 4,219,569 2.6
California serogroup viruses
Chikungunya
Dengue SEEG [2,12]
Japanese encephalitis
Murray Valley encephalitis
Rift Valley fever
Rocio
Ross River virus
Sindbis
St. Louis encephalitis
Venezuelan equine
encephalitis
Western equine encephalitis
(Continued)
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individual diseases that are a mapping priority, malaria (Plasmodium falciparum, P. vivax, and
P. knowlesi), HIV and tuberculosis. Table 1 shows the top 15 disease clusters (i.e. those in the
top right of Fig 2), representing 44 individual diseases, with their associated scores. Fig 3 dem-
onstrates that there exists a group of approximately 45 diseases that are the collective focus of
public health agencies. The 44 diseases prioritised by this study include all those diseases that
represent a significant cartographic challenge (i.e. those diseases requiring either species distri-
bution modelling approaches to produce occurrence maps or model-based geostatistics to pro-
duce prevalence maps, n = 33) identified by these public health agencies, save rabies and avian
influenza. The clusters are ranked in order, whilst the diseases within each cluster are alphabet-
ical and should be considered equal on the basis of this prioritisation.
The top ten priority clusters account for over 92% of all DALYs for those IDs which require
mapping (i.e. the 176 IDs identified); if this is expanded to the top 15 clusters containing 44
diseases to map, this value increases to 95% (Fig 4). Within these 44 diseases, 19 of the 29 ne-
glected tropical diseases (NTD) highlighted by the WHO are represented. Within the top ten
prioritised clusters, 14 individual diseases relate to these same NTDs [52,53]. The top 15 priori-
tised clusters include some diseases, such as the picornaviridae (polio), that have a low DALY
burden but a high public health ranking because they are high on the eradication agenda.
Disease burden
It was possible to establish a direct correspondence with GBD estimates for 34 of the 176 dis-
eases with a strong rationale for mapping as listed byHay et al. (2013) [44,45]. DALY estimates
were allocated to a further 132 diseases by linking diseases with ICD-10 codes [46] and their re-
spective GBD category definitions. Whilst these burden values are not accurate absolute values,
and should not be interpreted as such, this DALY allocation does allow relative burdens to be
determined. The remaining 11 diseases were given the baseline DALY allocation of 100, a value
not intended to represent an estimate of the “true”DALYs associated with these diseases, but
rather to distinguish them from diseases which were considered to cause a major burden in the
GBD analysis. It is safe to assume that if such diseases were not assigned a specific GBD classifi-
cation, their global impact on mortality and morbidity is relatively small.
In total, the 176 diseases with a strong rationale for mapping [1] represent over 230 million
DALYs, approximately 10% of the global DALY burden and 47% of the global ID DALY bur-
den. At the cluster level, HIV, malaria and tuberculosis represent 80% of the overall mapping-
disease DALY burden (Fig 5A). Apart from these three conditions, the only other IDs in the
top 50 highest DALYs globally are not currently recommended for mapping because they do
not show spatial variation in their occurrence and have insufficient data to map variation in
disease prevalence with model-based geostatistical analyses. The high-burden diseases not cur-
rently considered for mapping include respiratory diseases, meningitis, and many diarrhoeal
Table 1. (Continued)
Cluster (main diseases to map / total
diseases in cluster)
Diseases within cluster, to
map
Total cluster
DALYs
Average policy
score
Current global mapping
projects
West Nile fever
Yellow fever
* Indicates default null value.
MAP—Malaria Atlas Project; WHO—World Health Organization; GBD—Global Burden of Disease; GAHI—Global Atlas of Helminth Infections; SEEG—
Spatial Ecology and Epidemiology Group; APOC—African Programme for Onchocerciasis Control; GAT—Global Atlas of Trachoma
doi:10.1371/journal.pntd.0003756.t001
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infections. Alternative approaches to mapping broader symptom groupings (severe pneumo-
nia, severe diarrhoea and severe febrile illnesses) and then differentiating constituent disease
Fig 1. Hierarchical organisation of the 33 clusters. The 176 diseases with strong rationale for mapping were first sorted by taxonomy of pathogenic agent
(in orange) and then structured by common epidemiological and transmission characteristics into sub-groupings (in blue) and finally clusters (in red).
STH = soil transmitted helminth, VBD = vector borne disease.
doi:10.1371/journal.pntd.0003756.g001
Fig 2. Disease prioritisation. Plot showing the 33 clusters of diseases as ranked by burden of disease DALYs (y-axis—logarithmic scale) and mean policy
priority score of occurrence mapping and prevalence mapping diseases (x-axis—linear scale). The top ten clusters circled and numbered as identified in
Table 1. The size of the circle is determined by the total number of diseases contained and colour is based upon taxonomy (as outlined by Fig 1; the web
appendix contains the full disease listing for each cluster). The dashed guidelines are perpendicular to the axis along which prioritisation order for the clusters
was determined; those closer to the top right, along this axis, were prioritised higher.
doi:10.1371/journal.pntd.0003756.g002
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components, are being developed. Together, this would map 80% of all DALYs caused by
communicable diseases.
A higher resolution focus on the clusters excluding HIV, malaria and tuberculosis (Fig 5B)
shows that over 60% of DALYs associated with the 176 IDs are accounted for by the other top
ten prioritised clusters; approximately three quarters of the remaining DALYs are accounted
for when the remaining prioritised clusters of diseases are included.
Global health community interest
The treemap in Fig 5C displays the repartition of interest from the global health community
across the clusters. Interest was scored in terms of: 1) the stated priorities of a survey of assort-
ed public health stakeholders who are expected to be end-users of the maps, 2) status as a noti-
fiable disease, and 3) prominence in the academic literature.
A total of 20 diverse stakeholders were surveyed. This was found to be a sufficiently large
number to sample based on an analysis similar to a species accumulation curve that demon-
strates the diminishing returns from increasing sampling effort [54]. The number of new
Fig 3. A “species accumulation” curve showing the cumulative number of diseases of interest sampled by increasing numbers of public health
stakeholders examined. The diseases of interest of twenty global health stakeholders was indexed and plotted (see Methods). As additional organisations
are sampled beyond the fifteen used in this study, the number of unique diseases identified plateaus at around 42. Thus not all public health stakeholders
need to be sampled to capture the global diversity of diseases of public health interest.
doi:10.1371/journal.pntd.0003756.g003
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diseases reported levelled off at around 15 organisations sampled (Fig 3) and so the 20 organi-
sations used for this analysis was sufficient to capture the diseases of public health priority. Of
the 176 diseases recommended for mapping [1], 24% were prioritised by at least one public
health agency, and 55% were notifiable to at least one of the national disease control agencies.
Of those diseases that represent the greatest cartographic challenge, all were prioritised by at
least one public health agency and two thirds were notifiable diseases. Of the 176 diseases, thir-
ty diseases (17%) had an h-index [48] above 100 (with HIV having the highest h-index of 461),
while 64% of the diseases had an h-index of 50 or less. Of the occurrence mapping and preva-
lence mapping diseases, 30% had an h-index above 100 and only 37% had an h-index of 50
or less.
Unlike the DALY burden, which was allocated at the disease level (S1 Text), the stated prior-
ity diseases were often grouped to the cluster level by the surveyed stakeholders. For instance,
rather than specifying “Plasmodium vivax” or “visceral leishmaniasis” as a focus, “malaria” and
“leishmaniasis” would be more commonly stated targets. Each component disease of these
clusters would therefore be allocated a point, meaning that the number of component diseases
in each cluster strongly inflated the overall interest score allocated at the cluster aggregate. In-
terest scores were calibrated in the final prioritisation assessment to the number of diseases
classified as occurrence or prevalence mapping within each cluster (i.e. those requiring the
more advanced geostatistical techniques, see Methods for more details), so as to avoid being
unduly skewed by the size of the cluster.
Overall, malaria, HIV and tuberculosis were the leading clusters of interest, with scores of
11.8, 11 and 11, respectively. A further seven clusters received repeated interest, including
Fig 4. Cumulative percentage barplot indicating the cumulative percentage of DALYs accounted for by each cluster. The colouring is based upon
taxonomy, as in Fig 2. The red line indicates the top ten clusters, the dark green indicates the top 15.
doi:10.1371/journal.pntd.0003756.g004
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food-borne/water-borne bacteria (score = 8) and water-borne trematodes (7.7), trypanosomia-
sis (7.5), filariasis (6.2), picornaviridae (6), avian contact viruses (6), soil-transmitted helminths
(5.3) and leishmaniasis (5.2) all scoring highly, indicating their importance to the public health
community. These scores are relative and intended to reveal general trends across the clusters
rather than quantitatively reflect the weighting that any one institution places on a particular
disease.
Discussion
A review of all clinically significant IDs identified 176 with a strong rationale for mapping, of
which only 4% have been adequately mapped [1]. The current study was undertaken to define
a ruleset for determining which diseases, from a cartographic and public health perspective,
should be prioritised when sequentially addressing this shortfall. Diseases were clustered to-
gether based upon shared characteristics (such as basic taxonomic division and mode of trans-
mission) in order to consider together those diseases that would synergise operationally in
terms of data collection, covariate selection and methodology used. Given the large number of
diseases identified, prioritisation is necessary; we addressed this by evaluating both within the
context of disease burden as well as considering the diseases’ influence within public health or-
ganisations and the wider academic community. It is important to stress that the study was fo-
cussed on priorities for mapping, and was not a general prioritisation of IDs; this is particularly
important to emphasise given that a number of high-burden diseases, including meningitis,
pneumonia and some diarrhoeal diseases, were not included in the list of 176 diseases
[1,44,45].
Malaria is the infectious disease for which the most detailed and robust global risk maps
exist [13,29]. The work of the Malaria Atlas Project [33,55] along with a proliferation of nation-
al and local-scale studies [56] has established a mature and sophisticated methodological ap-
proach centred on the use of model-based geostatistics to generate continuous surfaces of risk.
This has been possible, in part, due to the long history of population-based malaria infection
prevalence surveys where researchers and control programmes have used microscopy or rapid
diagnostic tests to establish the proportion of randomly sampled individuals testing positive
for malaria parasitaemia [30,57]. Crucial for geospatial mapping, such data are increasingly
georeferenced with a latitude and longitude for each observation established via gazetteer
methods (recorded location names linked to digital atlases) or directly using Global Positioning
System (GPS) technology at the time of survey [58,59].
The high prioritisation of HIV and tuberculosis shown in the current study brings into
sharp focus the need for similar mapping activities to be established for HIV and tuberculosis.
All three diseases have an established history of routine and survey-based data collection that,
in comparison to many other diseases, is of relatively high quality and consistency, laying the
foundation for similar statistical mapping approaches to those used for malaria to be applied.
Fig 5. Plots indicating the relative importance of eachmapping cluster. (A) Area of each section is
determined by the total DALY contribution of each of the 33 clusters. Blue indicates a cluster contributing to
the top ten clusters to be prioritised, green indicates top 44 diseases (n = 5 clusters) and light green
represents the remaining disease clusters (n = 18). (B) Area of each section is determined by the total DALY
contribution of 30 clusters, with HIV, tuberculosis and malaria excluded. Blue indicates a cluster contributing
to the top ten clusters to be prioritised (n = 7), green indicates top 44 diseases (n = 5 clusters) and light green
represents the remaining disease clusters (n = 18). STH = soil-transmitted helminth, (B)—bacteria, (N)—
nematode, (Pl)—platyhelminth, (V)—virus. (C) Area of each section is determined by the total policy interest
score of each of the 33 clusters. Red indicates a cluster within the top ten to be prioritised, orange indicates
one of top 44 diseases (n = 5) and light pink represents the remaining disease clusters (n = 18). STH = soil-
transmitted helminth, (B)—bacteria, (N)—nematode, (Pl)—platyhelminth, (V)—virus.
doi:10.1371/journal.pntd.0003756.g005
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A cornerstone of HIV surveillance over the last several decades has been routine blood testing
for HIV infection in mothers attending sentinel antenatal clinics. Such data provide rich longi-
tudinal observations of prevalence in this demographic group and the potential exists to com-
bine these with cross-sectional data from nationally representative household surveys [60] to
generate optimal space-time models of the changing geographical pattern of infection across
individual countries. Unlike HIV and malaria, population-based tuberculosis prevalence test-
ing is not currently included as part of the major international survey programmes [58,61].
However, such surveys (reporting on the prevalence of bacteriologically-confirmed pulmonary
tuberculosis) have been undertaken in a number of high-burden countries in recent years, with
many more planned in the near future [62]. In a similar way to HIV, the prospect exists of a
mapping methodology that could combine survey-based data with the rich health-system
based data on new case notifications and other metrics, leveraging the respective strengths of
community- and facility-based data. A longer-term goal must be the development of a data as-
similation and modelling architecture for all three of these major global diseases to support ro-
bust and regularly updated global maps detailing their joint distribution and its evolution
though time which can be used to assess the impact of control and international financing ef-
forts [18].
The current analysis identifies a number of different NTDs as priority diseases for mapping,
a finding which is consistent with the emphasis given to mapping by the global NTD commu-
nity in order to geographically target NTDs interventions [63,64]. Specifically, for those NTDs
where morbidity control is the goal, including soil-transmitted helminths (STH) and schistoso-
miasis, interventions are most cost-effective when they are targeted to areas of highest trans-
mission [21]. For those NTDs which are identified for elimination, such as onchocerciasis and
lymphatic filariasis, it is essential to know where transmission occurs and when it has been suc-
cessfully halted following control measures. As a consequence of these operational require-
ments, large-scale mapping initiatives are underway for each of the main NTDs (Table 1). A
challenge for mapping the NTDs, and indeed for mapping many IDs, is the need to continually
update maps in order to help track the progress in control. As interventions reduce transmis-
sion levels and therefore distributions become more focalised, the need for mapping will
only increase.
Unsurprisingly, the top 44 diseases for prioritisation are dominated by those with the high-
est global burden. However, certain clusters stand out as having high public health attention
without a high burden, particularly the picornaviridae cluster and its constituent disease, polio.
Although cases are now restricted to a few hundred each year, polio has been identified as an
eradication target and is a high priority for many public health stakeholders despite recent ob-
stacles in the eradication schedule [65,66]. In these eradication and elimination scenarios, the
role of mapping changes subtly to both identifying areas where cases continue to occur, and in
highlighting potential future risks and improving surveillance [67]. Following a similar logic,
diseases such as dracunculiasis, African trypanosomiasis and onchocerciasis, in spite of rela-
tively low burdens, remain high policy priorities due to elimination efforts in various parts of
the globe [68,69]. These examples demonstrate the utility of the approach used in this study of
using assessments of the public health burden as well as metrics of public health attention.
The disease prioritisation methodology used here differs from existing approaches, such as
the “Delphi panel method”, in that it does not include a panel of experts scoring various criteria
associated with the diseases being considered [70–74]. In contrast, this study uses a simplified
methodology, placing importance in reproducibility and flexibility, using clearly defined rules
to assess available evidence and remove potentially subjective expert-opinion. The methods
employed are reliant on independent, third party information, and are assessed in a consistent
manner, which can easily respond to changes either in burden or public health focus. The
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relative importance of these diseases will most likely change over time, so an approach that can
easily accommodate this is preferable. Burden estimation using the GBD is crucial, since it is
the leading globally consistent measure by which to compare these various diseases and the ef-
fects of their many different clinical manifestations. Any global assessment of 301 causes of
mortality and morbidity, and associated sequelae, will be subject to the limitations of data avail-
ability and epidemiological understanding as well as model assumptions and implementation
[53,75,76], and will require frequent updates in a rapidly changing world. The technique pre-
sented here has the advantage of being rapidly updateable, and we will reproduce these num-
bers with each new iteration of the GBD project. As a consequence, public health authorities
can also easily create bespoke prioritisation lists based upon a selection of disease inclusion cri-
teria (such as those endemic to their particular country or region). This can more easily be
achieved with the availability of sub-national estimates of disease burden from the GBD study.
Country specific estimates of the interest scores can also be generated with greater specificity,
and can therefore avoid some of the potential biases resulting from the use of other countries
as representatives of each GBD region used in this study.
Additional factors that may influence the disease priority, such as potential economic im-
pact [77–79], were not used in this analysis because insufficient information was available to
include these metrics. The methodology outlined above benefits from two metrics that can be
applied globally to quantify DALYs and public health priority. As and when measures of addi-
tional disease impacts become available, they can and should be incorporated into assessments
such as this.
The study also identifies some high DALY groupings that do not have high-level policy in-
terest. Three groupings (Tick-borne (Bacterial), Tick-borne (Viral) and Mammal contact
(Viral)) have a cumulative high DALY burden, but relatively low policy rankings and therefore
are just outside the top 15 cluster listing. This may reflect the large number of diverse patho-
gens that make up these groupings, many of which are relatively restricted in distribution and
hence would not commonly be prioritised by globally focussed organisations. That said, the
high DALY value indicates that these diseases are of international interest, particularly when
secondary human-to-human transmission is a possibility such as with Lassa fever and Crimean
Congo Haemorrhagic Fever [80]. These conditions further advocate the utility of regional and
national level priority estimates.
The exclusion of diseases not suited for occurrence based mapping, and therefore omitted
from the prioritisation process (so called Option 1 diseases [1]), is entirely based on carto-
graphic considerations. Some of these diseases are inherently linked to human-to-human inter-
actions, others are endogenous in origin, with the pathogen essentially ubiquitous amongst
humans and only occasionally causing opportunist infections in certain scenarios, whilst some
have the potential to cause infection anywhere across the globe due to the cosmopolitan distri-
bution of their sources of infection, whether they be environmental or human based. Many of
these diseases can vary spatially, as evidenced by the African meningitis belt, although such
variation, when considered relative to the rest of the world, is due to differences in prevalence
or intensity, not presence or absence. Occurrence based mapping methods, such as boosted re-
gression trees, rely on binary presence/absence data. For conditions such as the common cold,
diphtheria or respiratory syncytial virus, which have the potential to occur across the globe,
these mapping techniques are ineffective. It is only through using more advanced methods,
such as model-based geostatistics, that maps analysing the variation in intensity of these dis-
eases can be produced. The limitation of this methodology is the amount of prevalence survey
data required, which for many diseases is not comprehensive or detailed enough to allow for
global analyses. Basic human related covariates, such as population density, urban extent pro-
files and national vaccination statistics can be used to explain a degree of the global variation in
Prioritising Infectious Disease Mapping
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0003756 June 10, 2015 16 / 21
these diseases, but fall short of the wealth of information that can be derived from comprehen-
sive global prevalence datasets, such as those available for malaria. As we continue to explore
additional data avenues, there will be an increasing number of diseases where such data
become available.
The disease prioritisation outlined in this study offers a logical framework for proceeding
with disease mapping, which reinforces the necessity of existing programmes and identifies
those diseases to focus on next (Table 1). Diseases which will form the initial focus of future
study comprise both those with the highest-burden and those of greatest concern to the global
health community. The initial top-priority diseases include a range of disease agents and trans-
mission routes, and therefore present a variety of challenges for mapping. The prioritisation
and clustering of these diseases presents a clear plan of action designed to maximise the effec-
tiveness and value of future cartographic efforts.
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